Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent.
The association between obesity and survival in non-Hodgkin lymphoma is unclear. Using the Ontario Cancer Registry we conducted a retrospective analysis of incident cases of aggressive-histology B-cell lymphoma treated with a rituximab-containing regimen with curative intent between 2008-2016. 6246 patients were included. On multivariable analysis the rate of all-cause mortality was lower for the overweight body mass index (BMI 25-29.9 kg/m2) (HR 0.85; 95%CI 0.77-0.95) and obese BMI (≥30 kg/m2) (HR 0.75; 95%CI 0.67-0.85) groups compared to the normal weight group (18.5-24.9 kg/m2). Binomial logistic regression analysis revealed a lower odds ratio (OR) of admission to hospital during treatment in the overweight (OR 0.84; 95%CI 0.75-0.95) compared to normal weight BMI group. In the largest cohort to date of aggressive-histology B-cell lymphoma patients treated with rituximab, increased BMI is associated with a survival advantage, and the magnitude of this effect increases from overweight to obese BMI.
['Stevenson|James K R|JKR|', 'Qiao|Yao|Y|', 'Chan|Kelvin K W|KKW|', 'Beca|Jaclyn|J|', 'Isaranuwatchai|Wanrudee|W|', 'Guo|Helen|H|', 'Schwartz|Deborah|D|', 'Arias|Jessica|J|', 'Gavura|Scott|S|', 'Dai|Wei Fang|WF|', 'Kouroukis|C Tom|CT|', 'Cheung|Matthew C|MC|']
D000328:Adult D000971:Antineoplastic Combined Chemotherapy Protocols D015992:Body Mass Index D015897:Comorbidity D004636:Emergency Service, Hospital D005260:Female D005500:Follow-Up Studies D006760:Hospitalization D006801:Humans D053208:Kaplan-Meier Estimate D016393:Lymphoma, B-Cell D008297:Male D008875:Middle Aged D009765:Obesity D009864:Ontario D050177:Overweight D000077982:Progression-Free Survival D012042:Registries D012189:Retrospective Studies D000069283:Rituximab
survival Obesity B-cell lymphoma body mass index rituximab